Mariella Rosalina Huaman Rivera

Ms. Mariella Rosalina Huaman Rivera

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2021 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
JHJorge Huaringa-Marcelo
Jorge Huaringa-Marcelo
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
ABAna Brañez-Condorena
Ana Brañez-Condorena
PVPamela Villacorta-Landeo
Pamela Villacorta-Landeo
DPDiego F Pinto-Ruiz
Diego F Pinto-Ruiz
AMAdelina Lozano Miranda
Adelina Lozano Miranda
Background and Aims: Vasoactive agents with endoscopic therapy are used to treat acute variceal bleeding (AVB). There are two main groups of vasoactive agents: terlipressin and vasopressin (T-V), and octreotide and somatostatin (O-S). However, the benefit/harm balance is unclear. Our aim was to assess the efficacy and safety of T-V versus O-S for the management of AVB. Methods: We performed a systematic search for randomized controlled trials (RCTs) in PubMed, Scopus, and CENTRAL. Our main outcomes were mortality and adverse events. Secondary outcomes were bleeding control, rebleeding, blood transfusion, hospital stay. We evaluated the certainty of evidence using GRADE methodology. Results: We included 21 RCTs. The risk of mortality (RR: 1.01; 95%CI: 0.83-1.22), bleeding control (RR: 0.96; 95%CI: 0.91-1.02; I 2 =53%), early rebleeding (RR: 0.91; 95%CI: 0.66-1.24: I 2 =0%), late rebleeding (RR: 0.94; 95 CI: 0.56-1.60; I 2 =0%), blood transfusion (MD: 0.04; 95%CI: -0.31-0.39; I 2 =68%) and hospital stay (MD: -1.06; 95%CI: -2.80-0.69; I 2 =0%) were similar between T-V and O-S groups. Only 15 studies reported adverse events, which were significantly higher in the T-V compared to the O-S group (RR 2.39; 95%CI: 1.58-3.63; I 2 =57%). The certainty of evidence was moderate for the main outcomes, and low or very low for others. Conclusions: In cirrhotic patients with AVB, those treated with T-V had similar mortality risk compared to O-S. However, the use of T-V showed an increased risk of adverse events compared to O-S.

Verified
Journal Article
Open access
PDF file
JBJoshuan J. Barboza
Joshuan J. Barboza
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
BMBeatriz Melgar
Beatriz Melgar
CDCarlos Diaz-Arocutipa
Carlos Diaz-Arocutipa
GVGerman Valenzuela-Rodriguez
German Valenzuela-Rodriguez
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Objective: We systematically assessed the efficacy of liraglutide in non-diabetic obese adults. Methods: Six databases were searched up to July 2021 for randomized controlled trials (RCTs) assessing liraglutide versus placebo in obese adults. Primary outcomes were body weight and body mass index (BMI). Secondary outcomes were treatment-emergent adverse events (TEAEs), hypoglycemic episodes, HbA1c, and blood pressure. Effect measures were risk ratio (RR) or mean difference (MD) with their confidence interval (95%CI). Random-effects models and inverse variance meta-analyses were used. Quality of evidence was assessed using GRADE. Results: Twelve RCTs (n = 8249) were included. In comparison to placebo, liraglutide reduced body weight (MD −3.35 kg; 95%CI −4.65 to −2.05; p < 0.0001), and BMI (MD −1.45 kg/m2; 95%CI −1.98 to −0.91; p < 0.0001). Liraglutide did not reduce TEAEs (RR 1.08; 95%CI 0.92 to 1.27; p = 0.25), and Hb1Ac (MD −0.76%; 95%CI −2.24 to 0.72; p = 0.31). Furthermore, it did not increase hypoglycemic episodes (RR 2.01; 95%CI 0.37 to 11.02; p = 0.28). Finally, liraglutide reduced systolic blood pressure (MD −3.07 mmHg; 95%CI −3.66 to −2.48; p < 0.0001) and diastolic blood pressure (MD −1.01 mmHg; 95%CI −1.55 to −0.47; p = 0.0003). Seven RCTs had a high risk of bias. Subgroup analyses by length of treatment and doses had effects similar to the overall analyses. Quality of evidence was low or very low for most outcomes. Conclusions: In non-diabetic obese adults, liraglutide reduced body weight, BMI and blood pressure in comparison to placebo. Adverse events, Hb1Ac levels and hypoglycemic episodes were not different than placebo.

21 April 2020 in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Verified
Journal Article
Open access
AQAntonio M. Quispe
Antonio M. Quispe
DPDiego F. Pinto
Diego F. Pinto
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
GBGilda M. Bueno
Gilda M. Bueno
AVAndree Valle-Campos
Andree Valle-Campos
El cálculo de tamaño de muestra es un aspecto esencial del diseño de estudios cuantitativos. Un adecuado tamaño de muestra nos permite determinar cuál es la mínima cantidad de participantes necesarios para probar nuestra hipótesis de interés. De esta manera, podemos reducir costos, maximizar el uso de nuestros recursos de investigación y garantizar la factibilidad del estudio. Contradictoriamente, a pesar de su relevancia muy pocos investigadores dominan esta habilidad. Esta revisión tiene por objeto revisar los conceptos básicos para realizar un cálculo de tamaño de muestra y compartir códigos de Stata y R específicamente diseñados para facilitar estos cálculos.

3 December 2021 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
LVLiz Eliana Veramendi-Espinoza
Liz Eliana Veramendi-Espinoza
JZJessica Hanae Zafra-Tanaka
Jessica Hanae Zafra-Tanaka
CTCrhistian Toribio-Dionicio
Crhistian Toribio-Dionicio
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
GPGabriela Pérez
Gabriela Pérez
WCWilmer Córdova-Calderón
Wilmer Córdova-Calderón
Objective To investigate the level of awareness of primary immunodeficiency diseases among physicians working at Instituto Nacional de Salud del Niño. Methods Cross-sectional study including pediatric residents and pediatricians working at the Instituto Nacional de Salud del Niño during the study period (2017-2019). Physicians working at the immunology unit and surgery departments were excluded. Three aspects of awareness of primary immunodeficiency diseases were investigated: education, general knowledge, and diagnostic suspicion and actions taken in the face of suspicion. Results [...] ABSTRACT Objective To investigate the level of awareness of primary immunodeficiency diseases among physicians working at Instituto Nacional de Salud del Niño. Methods Cross-sectional study including pediatric residents and pediatricians working at the Instituto Nacional de Salud del Niño during the study period (2017-2019). Physicians working at the immunology unit and surgery departments were excluded. Three aspects of awareness of primary immunodeficiency diseases were investigated: education, general knowledge, and diagnostic suspicion and actions taken in the face of suspicion. Results

1 June 2020 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
MPM. E. Pinto Paz
M. E. Pinto Paz
LLL. Bueno Lazo
L. Bueno Lazo
DPD. Carrera Palao
D. Carrera Palao
DRD. F. Pinto Ruiz
D. F. Pinto Ruiz
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
AQA. M. Quispe
A. M. Quispe
BACKGROUND: Chronic tuberculous granulomatous mastitis (CTGM) is a rare form of tuberculosis (TB) treated primarily with anti-TB drugs. Oncoplastic surgery (OS) has been proposed as adjuvant therapy for CTGM. METHOD: We followed for 1 year every CTGM patients and assessed the efficacy (defined as non-recurrence and no need for corticosteroids) and safety attributable to the standard anti-TB drugs therapy with and without OS. RESULTS: We analysed 128 CTGM cases, including 78 (61%) treated with OS plus anti-TB drugs and 50 (39%) with anti-TB drugs only. We observed a significantly higher efficacy among those exposed vs. unexposed to OS (100% vs. 92%; prevalence ratio [PR] 1.09, 95% CI 1.00-1.18), with no difference in the number of complications (21% vs. 8%; PR 2.56, 95% CI 0.91-7.26). We also observed that the incidence of post-operative complications decreased by 50% when OS was postponed from after Month 1 to after completing Month 2 of anti-TB drugs treatment (19% to 8%; PR 0.46, 95% CI 0.13-1.62). CONCLUSION: OS appears to represent an efficacious and safe adjuvant therapy when combined with anti-TB drugs in the treatment of CTGM patients, but clinical trials are needed to prove this observation.

1 May 2021 in JACC
Verified
Journal Article
Closed access
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
ATAstrid Tauma-Arrué
Astrid Tauma-Arrué
SLSilvana Loli-Guevara
Silvana Loli-Guevara
MRMariella Rosalina Huaman Rivera
Mariella Rosalina Huaman Rivera
JMJuan Carlos Mego
Juan Carlos Mego
PSPedro A. Segura-Saldaña
Pedro A. Segura-Saldaña